• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by TuHURA Biosciences Inc.

    10/31/25 11:31:09 AM ET
    $HURA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HURA alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    TuHURA Biosciences Inc

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    898920103

    (CUSIP Number)


    09/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    898920103


    1Names of Reporting Persons

    The Vanguard Group
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    PENNSYLVANIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    198,105.00
    7Sole Dispositive Power

    2,061,877.00
    8Shared Dispositive Power

    207,789.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,269,666.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.44 %
    12Type of Reporting Person (See Instructions)

    IA

    Comment for Type of Reporting Person:  The holdings reported herein include securities in the form of rights.The CUSIP Number listed throughout this filing is the CUSIP assigned to the Ordinary Shares of the Issuer.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    TuHURA Biosciences Inc
    (b)Address of issuer's principal executive offices:

    10500 University Center Drive, Suite 110, Tampa, FL, 33612
    Item 2. 
    (a)Name of person filing:

    The Vanguard Group
    (b)Address or principal business office or, if none, residence:

    100 Vanguard Blvd., Malvern, PA 19355
    (c)Citizenship:

    PA
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    898920103
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    2269666
    (b)Percent of class:

    4.44  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    198105

     (iii) Sole power to dispose or to direct the disposition of:

    2061877

     (iv) Shared power to dispose or to direct the disposition of:

    207789

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5%.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    The Vanguard Group
     
    Signature:Ashley Grim
    Name/Title:Head of Global Fund Administration
    Date:10/31/2025
    Get the next $HURA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HURA

    DatePrice TargetRatingAnalyst
    3/3/2025$13.00Buy
    H.C. Wainwright
    12/19/2024$11.00Buy
    Rodman & Renshaw
    11/5/2024$15.00Buy
    Maxim Group
    More analyst ratings

    $HURA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    TuHURA Biosciences, Inc. Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

    Phase 3 accelerated approval trial of IFx-2.0 as adjunctive therapy with Keytruda® (pembrolizumab) as a first-line therapy for advanced and metastatic Merkel cell carcinoma (MCC) is underway, conducted under Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA) Company's Delta Opioid Receptor (DOR) technology selected for an oral presentation, along with 2 poster presentations at the 67th Annual American Society of Hematology (ASH) Annual Meeting and Exposition, taking place in Orlando, Florida on December 6-9, 2025 TAMPA, Fla., Nov. 14, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 immuno-oncology company developing

    11/14/25 7:00:00 AM ET
    $HURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TuHURA Biosciences Discovery Research on Targeting the Delta Opioid Receptor (DOR) to Reprogram Myeloid-Derived Suppressor Cells (MDSCs) Selected for Oral Presentation at the 67th ASH Annual Meeting and Exposition

    Oral presentation highlights the first time it's been demonstrated that the DOR is expressed on tumor-associated MDSCs, and that DOR inhibition reprograms multiple mechanisms of MDSC- induced immunosuppression representing a new target in overcoming acquired resistance to cancer immunotherapy The first demonstration that DOR is expressed on Tumor-Associated Macrophages (TAMs), with DOR inhibition modulating their immunosuppressive capabilities Presentation from The Moffitt Cancer Center in collaboration with TuHURA scientists demonstrating the presence of the DOR on MDSCs from patients with myeloid dysplastic syndrome (MDS) and restoration of stem cell proliferation with DOR inhibition TAMPA

    11/3/25 9:01:00 AM ET
    $HURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TuHURA Biosciences, Inc. to Present at the 27th Annual H.C. Wainwright Global Investment Conference

    TAMPA, Fla., Aug. 20, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 immune-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that management will present at the 27th Annual H.C. Wainwright Global Investment Conference taking place September 8-10, 2025 in New York City. James Bianco, M.D., President and Chief Executive Officer of TuHURA Biosciences, is scheduled to present an overview and will be available for one-on-one meetings, as follows: 27th Annual H.C. Wainwright Global Investment Conference Date: Monday, September 8, 2025 Time: 2:30 PM Eastern Time Link: Click Here A replay of the presenta

    8/20/25 8:00:00 AM ET
    $HURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HURA
    SEC Filings

    View All

    SEC Form 10-Q filed by TuHURA Biosciences Inc.

    10-Q - TuHURA Biosciences, Inc./NV (0001498382) (Filer)

    11/14/25 7:20:46 AM ET
    $HURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TuHURA Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - TuHURA Biosciences, Inc./NV (0001498382) (Filer)

    11/14/25 7:10:26 AM ET
    $HURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form D filed by TuHURA Biosciences Inc.

    D - TuHURA Biosciences, Inc./NV (0001498382) (Filer)

    11/10/25 4:07:26 PM ET
    $HURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HURA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Tendler Craig

    4 - TuHURA Biosciences, Inc./NV (0001498382) (Issuer)

    3/19/25 7:13:50 PM ET
    $HURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Tendler Craig claimed no ownership of stock in the company (SEC Form 3)

    3 - TuHURA Biosciences, Inc./NV (0001498382) (Issuer)

    3/19/25 7:12:21 PM ET
    $HURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Hoffman Robert E.

    4 - TuHURA Biosciences, Inc./NV (0001498382) (Issuer)

    1/6/25 5:08:15 PM ET
    $HURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HURA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on TuHURA Biosciences with a new price target

    H.C. Wainwright initiated coverage of TuHURA Biosciences with a rating of Buy and set a new price target of $13.00

    3/3/25 7:23:43 AM ET
    $HURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rodman & Renshaw initiated coverage on TuHURA Biosciences with a new price target

    Rodman & Renshaw initiated coverage of TuHURA Biosciences with a rating of Buy and set a new price target of $11.00

    12/19/24 7:41:52 AM ET
    $HURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Maxim Group initiated coverage on TuHURA Biosciences with a new price target

    Maxim Group initiated coverage of TuHURA Biosciences with a rating of Buy and set a new price target of $15.00

    11/5/24 7:54:57 AM ET
    $HURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HURA
    Leadership Updates

    Live Leadership Updates

    View All

    TuHURA Biosciences, Inc. Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

    Phase 3 accelerated approval trial of IFx-2.0 as adjunctive therapy with Keytruda® (pembrolizumab) as a first-line therapy for advanced and metastatic Merkel cell carcinoma (MCC) is underway, conducted under Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA) Company's Delta Opioid Receptor (DOR) technology selected for an oral presentation, along with 2 poster presentations at the 67th Annual American Society of Hematology (ASH) Annual Meeting and Exposition, taking place in Orlando, Florida on December 6-9, 2025 TAMPA, Fla., Nov. 14, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 immuno-oncology company developing

    11/14/25 7:00:00 AM ET
    $HURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TuHURA Biosciences, Inc. Appoints Dr. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management

    Proven 20-year career in drug discovery and development track record leading to 12 pre-clinical/clinical candidates and 7 investigational new drug / clinical trial applications Extensive knowledge in the biochemistry and pharmacology of the Delta Opioid Receptor (DOR), the primary target in TuHURA's Antibody Drug Conjugate (ADC) and Antibody Peptide Conjugate (APC) technology platform Inventor of first-in-class spirocyclic DOR agonists as potential analgesics; clinical- stage products licensed to Pfizer Led the benevopran opioid-induced bowel dysfunction program to positive Phase IIb results: key value inflection point resulting in the acquisition of Adolor Corporation by Cubist Pharmaceutic

    4/7/25 8:24:00 AM ET
    $HURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HURA
    Financials

    Live finance-specific insights

    View All

    TuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

    Phase 3 IFx-2.0 accelerated approval trial as adjunctive therapy with Keytruda® (pembrolizumab) in 1st line therapy for advanced Merkel cell carcinoma (MCC) planning to initiate enrollment in Q2 2025 MCC Phase 3 trial to be conducted under Special Protocol Assessment (SPA) Agreement with FDA Acquisition of Kineta's Phase 2 ready, VISTA inhibiting antibody targeted for completion in Q2 2025 Expanded discovery team for first-in-class immune modulating Antibody Drug or Peptide Conjugate Program TAMPA, Fla., April 1, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overco

    4/1/25 8:00:00 AM ET
    $HURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HURA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by TuHURA Biosciences Inc.

    SC 13G - TuHURA Biosciences, Inc./NV (0001498382) (Subject)

    10/25/24 4:30:14 PM ET
    $HURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by TuHURA Biosciences Inc.

    SC 13G - TuHURA Biosciences, Inc./NV (0001498382) (Subject)

    10/25/24 4:28:34 PM ET
    $HURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by TuHURA Biosciences Inc.

    SC 13G - TuHURA Biosciences, Inc./NV (0001498382) (Subject)

    10/25/24 4:26:02 PM ET
    $HURA
    Biotechnology: Pharmaceutical Preparations
    Health Care